GLIAVAX: A stratified phase II clinical trial of avelumab and axitinib in patients with recurrent glioblastoma.

Bart Neyns,Laila Ben Salama,Gil Awada,Jennifer De Cremer,Julia Katharina Schwarze,Laura Seynaeve,Stephanie Du Four,Lydia Fischbuch,Anne-Marie Vanbinst,Hendrik Everaert,Alex Michotte,Anne Rogiers,Peter Theuns,Johnny Duerinck

GLIAVAX: A stratified phase II clinical trial of avelumab and axitinib in patients with recurrent glioblastoma.

2019

Bart Neyns
Laila Ben Salama
Gil Awada
Jennifer De Cremer
Julia Katharina Schwarze
Laura Seynaeve
Stephanie Du Four
Lydia Fischbuch
Anne-Marie Vanbinst
Hendrik Everaert
Alex Michotte
Anne Rogiers
Peter Theuns
Johnny Duerinck

2034Background: Patients (pts) with recurrent glioblastoma (rGB) have a poor prognosis, and no treatment option demonstrated to improve survival in a randomized trial. Axitinib (AXI), an oral VEGFR...

Keywords:

Avelumab
Clinical trial
Glioblastoma
Axitinib
Oncology
Pathology
Medicine
Internal medicine
treatment options
in patient
Randomized controlled trial
poor prognosis
recurrent glioblastoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations